The genetic component of depression is larger in women than men
Uma pesquisa australiana com quase 200 mil amostras de DNA revelou que mulheres carregam aproximadamente o dobro de marcadores genéticos associados à depressão em comparação aos homens — cerca de 13 mil variantes contra 7 mil. Publicado na Nature Communications, o estudo do Instituto de Pesquisa Médica Berghofer começa a iluminar uma disparidade clínica há muito observada, mas pouco compreendida em sua origem biológica. A descoberta sugere que a depressão não é uma experiência uniforme entre os sexos, e que a medicina do futuro pode precisar reconhecer essa diferença para tratar com mais precisão os mais de 300 milhões de pessoas afetadas pela condição no mundo.
- Mulheres apresentam quase o dobro de variantes genéticas ligadas à depressão em relação aos homens, revelando uma assimetria biológica profunda e até então mal compreendida.
- Parte dessas diferenças genéticas parece afetar vias metabólicas e hormonais, o que pode explicar por que mulheres com depressão frequentemente relatam alterações de peso, energia e apetite além dos sintomas de humor.
- A pesquisa expõe uma falha histórica: a maioria dos medicamentos e estudos clínicos foi desenvolvida com base em participantes do sexo masculino, deixando lacunas significativas no tratamento feminino.
- Pesquisadoras do projeto apontam que compreender os fatores genéticos específicos de cada sexo abre caminho para tratamentos personalizados, superando a abordagem genérica que domina a psiquiatria atual.
- Com mais de 300 milhões de pessoas vivendo com depressão globalmente — e mulheres em proporção desproporcional —, os achados reposicionam a biologia como peça central na busca por terapias mais eficazes e equitativas.
Pesquisadores australianos do Instituto Berghofer publicaram na Nature Communications um dos maiores estudos genéticos sobre depressão já realizados, analisando o DNA de quase 200 mil pessoas diagnosticadas com a condição. O resultado central é revelador: mulheres apresentam cerca de 13 mil variantes genéticas associadas à depressão, enquanto nos homens esse número cai para aproximadamente 7 mil — quase a metade.
A descoberta começa a explicar biologicamente algo que clínicos já observavam há décadas: a depressão acomete mulheres com muito mais frequência, mas os mecanismos por trás dessa diferença permaneciam obscuros. O estudo indica que a própria arquitetura genética da doença difere entre os sexos, e que algumas dessas variantes influenciam vias metabólicas e hormonais. Isso pode justificar por que mulheres com depressão frequentemente relatam sintomas como variações de peso, oscilações de energia e mudanças no apetite — um perfil clínico distinto do observado em homens.
A pesquisadora Jodi Thomas, que liderou o projeto, destacou que reconhecer esses fatores genéticos específicos abre caminho para tratamentos mais individualizados. Sua colega Brittany Mitchell foi além, apontando um problema estrutural na medicina: historicamente, grande parte dos medicamentos e pesquisas clínicas foi desenvolvida com foco em participantes do sexo masculino, o que pode tornar os tratamentos atuais menos eficazes — ou com efeitos colaterais diferentes — para mulheres.
Com mais de 300 milhões de pessoas vivendo com depressão no mundo, segundo a Organização Mundial da Saúde, e mulheres representando uma parcela desproporcionalmente alta desse total, os achados têm implicações amplas. O horizonte apontado pelo estudo é o de uma medicina que abandone a abordagem única para todos e passe a considerar a biologia individual — e sexual — de cada paciente como ponto de partida para o tratamento.
Australian researchers have identified a significant biological difference in how depression takes root: women carry nearly twice as many genetic markers linked to the condition as men do. The finding, published this week in Nature Communications, emerged from one of the largest genetic studies of its kind, analyzing DNA from almost 200,000 people diagnosed with clinical depression. Scientists at the Berghofer Medical Research Institute in Australia identified roughly 13,000 genetic variants associated with depression in women, compared to about 7,000 in men.
The discovery matters because depression has long been known to strike women more frequently than men, yet the biological reasons have remained largely opaque. Clinicians and researchers understood the pattern without fully grasping its mechanics. This study begins to fill that gap, suggesting that the genetic architecture of depression itself differs between the sexes in ways that could reshape how the condition is treated.
Some of these genetic differences appear to influence biological pathways involved in metabolism and hormone production. This finding may help explain a pattern clinicians have observed for years: women with depression often report metabolic symptoms alongside their mood disturbance—weight fluctuations, shifts in energy levels, changes in appetite. The genetic variants may be creating a distinct disease signature in women, one that looks somewhat different from depression in men.
Researcher Jodi Thomas, who led the project, emphasized that understanding these sex-specific genetic factors opens a door to more tailored treatment. "The genetic component of depression is larger in women than in men," Thomas said. Recognizing the shared and unique genetic influences in each sex provides clearer insight into what actually causes depression and creates a pathway toward treatments designed for individual patients rather than one-size-fits-all approaches.
The research also surfaces a historical problem in medicine: most drug development and clinical research has centered on male participants. Brittany Mitchell, another researcher on the team, noted that until now, there has been no consistent body of evidence explaining why depression affects women and men differently, or what role genetics plays in that divergence. "Many of the medications we have today, and much of the research we've conducted, has focused primarily on men or male study participants," Mitchell observed. This bias means that treatments developed and tested mainly on men may not work as effectively for women, or may produce different side effects.
Clinical depression, formally known as major depressive disorder, ranks among the world's most common mental health conditions. The World Health Organization estimates that more than 300 million people globally live with depression. Women make up a disproportionate share of that number, and this genetic research suggests biology plays a substantial role in that disparity.
The implications extend beyond understanding why women get depressed more often. If genetic differences between men and women shape how depression manifests and responds to treatment, then future medications and therapies could be designed with those differences in mind. A woman experiencing depression with metabolic symptoms might benefit from a different intervention than a man with the same diagnosis. The path forward involves moving away from generic treatments toward medicine tailored to the actual biology of the individual patient.
Notable Quotes
The genetic factor of depression is greater in women than in men, and understanding these shared and unique genetic influences opens the way toward more personalized treatments.— Jodi Thomas, lead researcher
Until now, there has been no consistent research explaining why depression affects women and men differently, and many medications and research have focused primarily on male participants.— Brittany Mitchell, researcher
The Hearth Conversation Another angle on the story
Why does it matter that women have more genetic markers for depression? Isn't depression depression?
Because the markers don't just explain prevalence—they hint at mechanism. If women's depression involves different genetic pathways, especially ones tied to metabolism and hormones, then the disease itself may be operating differently in their bodies. A treatment that works for one may not work for the other.
So you're saying we've been treating women's depression with drugs designed for men?
Essentially, yes. Most drug development and clinical trials have centered on male participants. We've built our toolkit on male biology, then applied it universally. This study suggests that's a mismatch.
The study found 13,000 markers in women versus 7,000 in men. That's a huge gap. What does that actually mean?
It means the genetic landscape is denser in women. More variants, more points where things can go wrong or interact. It's not that men don't have genetic risk—they do—but women's genetic risk appears more complex and more abundant.
Could this lead to different medications for women?
That's the hope. If you understand that a woman's depression involves metabolic pathways in a way a man's might not, you could design drugs that target those specific pathways. Instead of one antidepressant for everyone, you might have treatments calibrated to sex-specific biology.
What about women who don't experience those metabolic symptoms?
That's the next question. This study identifies patterns at the population level, but depression is individual. Some women will fit the metabolic profile, others won't. The real work is figuring out which women need which treatments—and that requires more research, more granularity.
How long until this changes actual clinical practice?
That's uncertain. The science has to be replicated, validated, and then integrated into drug development pipelines. But the door is open now. For the first time, we have evidence that depression's genetic basis differs by sex. That changes the conversation.